Market revenue in 2023 | USD 572.0 million |
Market revenue in 2030 | USD 1,101.0 million |
Growth rate | 9.8% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 55.84% in 2023. Horizon Databook has segmented the UK biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
The market in the UK is lucrative owing to tax credits and various expansion strategies implemented in the developed countries. For instance, in the UK, there are two tax credits for large companies and small and medium-sized companies.
The large companies can claim 30% deducible from the income of their R&D expenditure. In case of small- and medium-sized enterprises, it is 225% for R&D expenditure. In March 2015, the U.S. FDA issued a guidance stating the need for drug companies to use e-informed consent in clinical trials.
In alignment with this suggestion, the UK Health Research Authority (HRA) approved use of Mytrus Enroll platform in a clinical trial. The UK is among the top five countries to invest in clinical trials and related activities.
Horizon Databook provides a detailed overview of country-level data and insights on the UK biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into UK biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account